pyrazines has been researched along with Cytomegalovirus Infections in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kaszynski, RH; Matsumoto, S; Sakai, K; Sato, N; Shiraki, K; Takemoto, M | 1 |
| Anaclerico, B; Annino, L; Arcese, W; Avvisati, G; Cerchiara, E; Chierichini, A; Cudillo, L; De Fabritiis, P; Dentamaro, T; Giannotti, F; Marchesi, F; Mengarelli, A; Monarca, B; Montefusco, E; Petti, MC; Picardi, A; Porrini, R; Romeo, A; Tendas, A; Tirindelli, MC | 1 |
| Dessanti, ML; Ensoli, F; Gumenyuk, S; Marchesi, F; Maschio, M; Mengarelli, A; Palombi, F; Pimpinelli, F; Pisani, F; Romano, A; Spadea, A | 1 |
| Boothpur, R; Brennan, DC; Torrence, S | 1 |
| Blanco, B; Caballero-Velázquez, T; Inogés, S; Pérez-Simón, JA; Sánchez-Abarca, LI; Santamaría, C | 1 |
| Goulston, C; Hanson, KE; Kim, JH; Lampas, M; Sanders, S; Tricot, G; Zangari, M | 1 |
1 review(s) available for pyrazines and Cytomegalovirus Infections
| Article | Year |
|---|---|
Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; COVID-19 Testing; Cytomegalovirus Infections; Humans; Influenza, Human; Pyrazines; SARS-CoV-2 | 2022 |
5 other study(ies) available for pyrazines and Cytomegalovirus Infections
| Article | Year |
|---|---|
High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Cohort Studies; Cytomegalovirus Infections; Dexamethasone; Doxorubicin; Humans; Immunocompromised Host; Incidence; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2014 |
Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytomegalovirus Infections; Dexamethasone; Doxorubicin; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Vincristine | 2014 |
Bortezomib does not reduce ABO-isoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization.
Topics: ABO Blood-Group System; Antiviral Agents; Blood Group Incompatibility; Boronic Acids; Bortezomib; Cytomegalovirus Infections; Doxorubicin; Ganciclovir; Hemagglutinins; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Valganciclovir | 2009 |
Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; In Vitro Techniques; Interferon-gamma; Lymphocyte Activation; Lymphocyte Depletion; Proteasome Inhibitors; Pyrazines; T-Lymphocytes; Transplantation, Homologous | 2011 |
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Risk Factors; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Viral Load; Viremia; Virus Activation | 2012 |